IRRA - PT. Itama Ranoraya Tbk

Rp 2.100

0 (0%)

JAKARTA – PT Itama Ranoraya Tbk (IRRA), the health devices distributor, displays an impressive performance with a 611.6% and 1,271% surge in its revenue and net profit in H1 2021 compared to the achievements made in H1 2020. Marketing Director of Itama Ranoraya, Hendry Herman, discloses this positive news in a press release, quoted Thursday (5/8).

It is mentioned that a considerable level of revenue growth is generated through the retail segment (non-State Budget/State Budget). Specifically, it includes non-electromedical health devices and in-vitro diagnostic products. “The revenue is reported to jump from IDR 79.4 billion to IDR 565.18 billion, while the net profit soars from IDR 3.7 billion to IDR 50.74 billion,” Herman confirms.

According to Herman, the skyrocketing in-vitro product sales, reaching 613.9%, is an outcome of the surge in demand for the COVID-19 antigen test kit (Panbio). Panbio sales throughout the first half of 2021 are made up of 5.5 million units, meeting the target of 5 to 10 million units.

Other in-vitro products that contribute to the revenue gain include reagents, apheresis machines (for processing convalescent plasma), non-COVID-19 rapid test kits, and non-medical health equipment like syringes. (LK/ZH)